Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:THEMISMED

THEMIS MEDICARE LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹124.00
at close · 21 Sept 2026
▲ 1.95 (+1.60%)

Latest filings

  1. Record date fixed for FY26 final dividend · Corporate Actions
  2. AGM notice published; 56th AGM set for 30 Sep 2026 · Compliance
  3. Themis Medicare 56th AGM notice on Sep 30, 2026; dividend proposed · Board & Shareholder Meetings
  4. Notice of 56th AGM and Annual Report for FY 2025-26 · Board & Shareholder Meetings
  5. Themis Medicare files FY26 Annual Report, 56th AGM on 30 Sept 2026 · Board & Shareholder Meetings
  6. Themis Medicare 56th AGM Notice and Annual Report FY 2025-26 · Board & Shareholder Meetings
  7. Clarification on unusual trading volume — no pending disclosures · Regulatory & Legal
  8. NSE flags unusual trading volume in Themis Medicare; seeks clarification · Compliance
  9. Update of Company Secretary email ID and RTA email ID · Compliance
  10. Newspaper publication of Q1 FY27 financial results · Compliance
  11. Disclosure of authorized persons for materiality determination · Compliance
  12. Q1 FY27 results, profit on share sale, Company Secretary change · Board & Shareholder Meetings
  13. Themis Medicare Q1 profit jumps on stake sale; new Company Secretary appointed · Management Changes
  14. Themis Medicare Q1 FY27: PAT turns positive on Rs 99.67 cr exceptional gain · Results
  15. Themis Medicare Q1 PAT at Rs 28.74 cr on share sale gain, new CS appointed · Board & Shareholder Meetings
  16. Promoter trust pledges 30 lakh more shares of Themis Medicare · Ownership Changes
  17. Board meeting on 13 Aug 2026 to consider Q1 FY27 results · Results
  18. Vividhmargi Investments pledges 30 lakh shares of Themis Medicare · Ownership Changes
  19. Promoter Vividhmargi Trust pledges 27.49% stake in Themis Medicare · Ownership Changes
  20. The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 21, 2026 for Vividhmargi Trust · Ownership Changes
  21. The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 20, 2026 for Vividhmargi .... · Ownership Changes
  22. Vividhmargi Investments releases pledge on 15 lakh Themis Medicare shares · Ownership Changes
  23. Routine filing: Demat certificate submitted for Q1 FY27 · Compliance
  24. Themis Medicare files Reg 74(5) demat certificate with BSE and NSE for June 2026 quarter · Compliance
  25. Promoter Vividhmargi Trust pledges 27.49 percent stake in Themis Medicare · Ownership Changes
  26. Themis Medicare: Promoter Vividhmargi Trust pledges 27.49% shares · Ownership Changes
  27. Vividhmargi Trust pledges 27.49 percent Themis Medicare shares to debenture trustee · Ownership Changes
  28. Trading window closes July 1 ahead of Q1 FY27 results · Compliance
  29. Trading Window Closed from July 1 for Q1 FY27 Results · Compliance
  30. Themis Medicare clarifies on volume spike, says no pending disclosure · Regulatory & Legal
  31. Volume surge prompts NSE query to Themis Medicare · Regulatory & Legal
  32. Annual Secretarial Compliance Report for the financial year ended 31st March, 2026 · Compliance
  33. Themis Medicare Limited has informed the Exchange about Copy of Newspaper Publication · Compliance
  34. Newspaper Publication of Audited Standalone and Consolidated Financial Results for the quarter and year ended 31.03.2026 · Compliance
  35. Please refer to the attachment. · Results
  36. Themis Medicare Limited has informed the Exchange about Investor Presentation · Investor Communications
  37. Please refer to the Investor Presentation of the Company for the quarter ended 31.03.2026 · Investor Communications
  38. 1. Approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2026 together with the Report issued by the Statutory Auditors, M/s. Krishaan .... · Results
  39. Themis Medicare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. · Results
  40. Themis Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve Standalone and Consolidated .... · Results
  41. Themis Medicare Limited has informed the Exchange about General Updates · General
  42. Please refer to the attachment. · Management Changes
  43. Themis Medicare Limited has informed the Exchange about Copy of Newspaper Publication · Compliance
  44. Dr. Dinesh S. Patel has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. · Compliance
  45. Themis Medicare Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 · Compliance
  46. Themis Medicare Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results. · Board & Shareholder Meetings
  47. Vividh Margi Investments Pvt ltd has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in respect of any acquisition made in reliance upon exemption provided for in regulation 10 of SEBI (SAST) Regulations, 2011. · Ownership Changes
  48. Themis Medicare Limited has informed the Exchange about General Updates · General
  49. Themis Medicare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 · Compliance
  50. Themis Medicare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 · Compliance
All filings ↓
Ask Nexa about THEMIS MEDICARE LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹332 Cr over the trailing twelve months.

Market Cap
₹1,142 Cr
P / E (TTM)
28.6×
EV / EBITDA
20.9×
Div Yield
0.40%
Growth
8.2%▲
Revenue 5y CAGR
PAT -49.8% · EBITDA -30.1%
Quality
10.7%·
ROCE (5y median)
ROE 11.5% · margin 2.6%
Leverage
0.25·
Debt / Equity · low
Net debt ₹96 Cr
Revenue FY21→FY26
1.5×▲
Margin −15.1 pts
₹231 Cr → ₹342 Cr
Cash conversion
0.47×▼
Operating cash ÷ profit · 5 yrs
₹96 Cr on ₹204 Cr
Moves on a normal day
1.66%·
Median daily move
Last 268 sessions · filing days run larger
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#84/170
P/B#75/164
ROCE#160/183
ROE#145/171
Debt / Equity#110/171
EBITDA margin#5/165
Revenue growth#134/161
Profit growth#20/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Nothing stands out in the filed numbers.
Concerns
Profit shrinking over 5 years (-50% a year)
Erratic profits — up in only 1 of the last 5 years
Returns on capital 10.7% (5-year median)
#160 of 183 in Pharmaceuticals on the latest reported figures · down from 18.4% in FY21
Over 5 years it reported ₹204 Cr of profit and ₹96 Cr of operating cash — 0.47×
Less than 60p of every ₹1 of profit arrived as cash
Heavy working capital — 222 days of cash tied up
Customers are taking longer to pay — 123 → 190 days of receivables
FY21 → FY26
EPS grew slower than profit — the share count rose (bonus or dilution)

Charts

How has the market priced it — with filings on the timeline?

THEMISMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from THEMIS MEDICARE LTD.'s filed financials and exchange disclosures

What does THEMIS MEDICARE LTD. do?

THEMIS MEDICARE LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol THEMISMED.

Is THEMIS MEDICARE LTD. profitable?

Yes. Over the trailing twelve months THEMIS MEDICARE LTD. reported a net profit of ₹40 Cr on revenue of ₹332 Cr.

Does THEMIS MEDICARE LTD. pay a dividend?

Yes. The dividend yield is 0.40% at the current price. It paid out 402% of its profit as dividend in FY26.

Is THEMIS MEDICARE LTD. debt-free?

No. Debt stands at 0.25× equity, and it carries net debt of ₹96 Cr. That is lower than 36% of its 171 Pharmaceuticals peers.

Is THEMIS MEDICARE LTD. expensive compared with its peers?

On trailing P/E, THEMIS MEDICARE LTD. ranks 84 of 170 in Pharmaceuticals — cheaper than 51% of them, against an industry median of 29.6×. This is a position, not a valuation judgement.

How much does the THEMIS MEDICARE LTD. share price move in a day?

On a typical session THEMIS MEDICARE LTD. moves 1.66% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.

Where can I track THEMIS MEDICARE LTD.'s announcements?

Every NSE and BSE filing by THEMIS MEDICARE LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.